Researchers have created a novel computational tool called the Lineage Maturation Index (LMI) to measure how cellular differentiation changes in response to treatments or genetic shifts. By applying this new method to large-scale drug databases, the team successfully identified mebendazole, a widely used antiparasitic medication, as a promising candidate for differentiation therapy in acute myeloid leukemia. Laboratory testing demonstrated that this drug triggers significant maturation in both leukemia cell lines and primary patient samples while successfully extending the lifespan of leukemia-bearing animal models. Because standard chemotherapy often causes severe bone marrow toxicity, this discovery highlights how repurposing safe, well-tolerated medications can offer a much-needed, low-toxicity alternative for vulnerable cancer patients.
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy characterized by the accumulation and tissue infiltration of abnormally differentiated, immature myeloid blast cells. Standard cytarabine- and anthracycline-based chemotherapies have remained the primary treatment for decades; however, their non-selective cytotoxicity causes severe myelosuppression and systemic toxicity in both healthy and leukemic hematopoietic cells. Furthermore, while acute promyelocytic leukemia (APL) is successfully managed with targeted differentiation therapies (such as all-trans retinoic acid), effective differentiation chemotherapies for non-APL AML subtypes remain lacking.
Preclinical and translational research in your sources highlights the repurposing of anthelmintic benzimidazole derivatives as promising, low-toxicity agents against AML:
1. Mebendazole (MBZ): Terminal Differentiation & Oncogenic Factor Degradation
Lineage Maturation & Differentiation Therapy: Using a computational Lineage Maturation Index (LMI) screen, mebendazole was identified as a potent inducer of terminal differentiation in AML. In primary blasts from human AML patients harboring diverse genetic mutations (FLT3-ITD, NPM1, IDH1, and MLL rearrangements), MBZ treatment significantly upregulated mature myeloid surface markers (CD11b, CD11c, and CD14) and restored granulocytic/monocytic morphology, including chromatin condensation and cytoplasmic granule accumulation.
c-MYB Proteasomal Degradation: Gene expression profiling revealed that MBZ targets c-MYB, an oncogenic transcription factor essential for leukemic stem cell proliferation and maturation arrest. MBZ promotes the proteasomal degradation of c-MYB, suppressing leukemic colony formation by over 80%.
Hedgehog/GLI Pathway Blockade: MBZ binds the ATP-binding site of HSP70/HSP90 chaperones, triggering the proteasomal degradation of GLI1 and GLI2 transcription factors. This downregulates Hedgehog promoter activity, sensitizes leukemic cells to cytarabine, and synergizes with the small-molecule GLI inhibitor GANT-61.
Off-Label Clinical Evidence: In an off-label clinical setting, oral MBZ monotherapy administered to a patient with refractory AML led to a rapid reduction in peripheral blood leukemic blast counts accompanied by decreased intracellular GLI2 protein levels.
Immune Activation & In Vivo Survival: MBZ stimulates CD14⁺ monocytic cells toward a proinflammatory (M1) phenotype via ERK1/2 and TLR8-dependent inflammasome activation, boosting T-cell-mediated tumor cell killing. In aggressive THP-1 AML xenograft mouse models, oral MBZ extended median survival from 49 days (control) to 76 days.
2. Albendazole (ABZ): Non-APL Monocytic Differentiation
KLF4-DPYSL2A Axis: High-throughput chemical screens identified albendazole as a key driver of terminal differentiation in non-APL AML cells, directing blasts into mature monocytes via stimulation of the Krüppel-like factor 4 (KLF4) – dihydropyrimidinase-like 2A (DPYSL2A) signaling axis.
SIRT3-Mediated Apoptosis: In leukemic cells, ABZ induces SIRT3 degradation, generating reactive oxygen species (ROS) that activate p38 MAPK, downregulate tristetraprolin (TTP), and upregulate TNF-α to trigger caspase-dependent apoptosis.
3. Flubendazole (FLBZ): Microtubule Disruption & Chemotherapy Synergy
Nanomolar Cytotoxicity: Flubendazole exhibits potent antiproliferative and apoptotic activity against AML cell lines (OCI-AML2, U937, THP-1) and primary AML patient samples at nanomolar concentrations.
Bypassing P-Glycoprotein Resistance: FLBZ binds tubulin at a site distinct from Vinca alkaloids, maintaining full cytotoxicity in leukemic cells that overexpress P-glycoprotein (P-gp) efflux pumps.
Combinatorial Synergy: FLBZ demonstrates strong synergistic cytotoxicity when combined with vinblastine or vincristine, significantly delaying AML xenograft tumor progression in vivo compared to single-agent administration.
4. Safety & Hematopoietic Selectivity
Across multiple studies, benzimidazole derivatives demonstrate marked selectivity for malignant blasts over normal tissues. At therapeutic concentrations, MBZ and ABZ show negligible toxicity toward healthy CD34⁺ cord blood progenitor cells and normal peripheral blood mononuclear cells, offering a wider therapeutic window than conventional cytotoxic agents.
Benzimidazole Malignancy Efficacy
Beyond Acute Myeloid Leukemia (AML), repurposed anthelmintic benzimidazole derivatives demonstrate significant, multi-targeted efficacy across a spectrum of hematological malignancies, including Multiple Myeloma (MM), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Lymphomas.
1. Multiple Myeloma (MM)
Multiple myeloma is characterized by frequent remissions and relapses driven by acquired multidrug resistance and rare myeloma stem-cell populations. Benzimidazoles address these hurdles through distinct molecular pathways:
Mebendazole (MBZ) & the USP5/c-Maf Axis: Upregulation of the oncogenic transcription factor c-Maf is a major driver of myeloma cell proliferation. MBZ inhibits the deubiquitinase USP5, leading to the targeted proteasomal degradation of c-Maf and induction of apoptosis (elevated cleaved caspase-3 and PARP). In MM mouse xenograft models, oral MBZ (50–100 mg/kg) produced dose-dependent tumor suppression without overt toxicity and synergized with chemotherapeutics like daunorubicin.
Albendazole (ABZ) & Reversal of Bortezomib Resistance: ABZ suppresses the NF-κB signaling pathway (downregulating p65 and phospho-p65) and depletes ALDH1⁺ multiple myeloma stem-like cells (MMSCs), which are responsible for drug resistance. Co-administering ABZ with the proteasome inhibitor bortezomib re-sensitizes resistant cells and induces synergistic G2/M phase cell cycle arrest.
Flubendazole (FLBZ) & P-Glycoprotein Bypass: FLBZ exhibits potent cytotoxicity across diverse MM cell lines at nanomolar concentrations. Because FLBZ binds tubulin at a site distinct from Vinca alkaloids, its activity is unaffected by P-glycoprotein (P-gp / MDR1) efflux pump overexpression, allowing it to remain fully effective in vinblastine-resistant myeloma cells.
2. Chronic Myeloid Leukemia (CML)
Standard CML management relies on tyrosine kinase inhibitors (TKIs) like imatinib, but mutations in the ABL1 kinase domain often lead to treatment failure:
Overcoming TKI Resistance: Combining MBZ with TKIs (imatinib or dasatinib) overcomes resistance in K562 CML cells—including those harboring the T315I gatekeeper mutation—by inducing cell cycle arrest and apoptosis.
miR-150-5p / MYB Axis: CML stem cell differentiation and TKI resistance are regulated by the miR-150-5p / MYB transcriptional loop. MBZ inactivates the MYB proto-oncogene, suppressing leukemic cell cycle progression.
3. Acute Lymphoblastic Leukemia (ALL)
Chemoresistant T-ALL: In preclinical models of T-cell ALL (CCRF-CEM and its chemoresistant derivative CEM/C1), MBZ markedly reduced cell proliferation and systemic lymphoblast counts in vivo.
Bypassing Taxane/Epothilone Resistance: ABZ retains full cytotoxic activity against epothilone- and paclitaxel-resistant leukemic lymphoblasts (e.g., CEM/dEpoB300), offering a salvage strategy when conventional antimitotic agents fail.
4. Lymphomas (DLBCL & Non-Hodgkin Lymphoma)
Fenbendazole (FBZ) Case & Preclinical Synergy: In a published clinical case report, an 83-year-old patient with Stage IVa Diffuse Large B-Cell Lymphoma (DLBCL) who declined standard chemotherapy experienced significant tumor regression on PET/CT imaging following self-administered FBZ. In animal models, FBZ combined with supplemental vitamins significantly inhibited human lymphoma xenograft growth in SCID mice.
FDA-Approved Derivative (Bendamustine): Synthesized with a benzimidazole ring structure, bendamustine is already FDA-approved for Chronic Lymphocytic Leukemia (CLL), MM, and indolent non-Hodgkin lymphoma, demonstrating superior response rates (68% vs 31%) and extended progression-free survival compared to chlorambucil.
Golla, U., Patel, S., Shah, N., Talamo, S., Bhalodia, R., Claxton, D., Dovat, S., & Sharma, A. (2024). From deworming to cancer therapy: Benzimidazoles in hematological malignancies. Cancers, 16(20), Article 3454. https://pubmed.ncbi.nlm.nih.gov/39456548/
Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for differentiation therapy of acute myeloid leukemia identified by a Lineage Maturation Index. Scientific Reports, 9, Article 16775. https://doi.org/10.1038/s41598-019-53290-3